
Myomo (MYO) Stock Forecast & Price Target
Myomo (MYO) Analyst Ratings
Bulls say
Myomo Inc has demonstrated a positive trend in its reimbursement pipeline, increasing from 1,389 units in Q4 to 1,611 units in Q1, indicating growing interest and demand for its myoelectric orthosis products. Additionally, the company's strategic focus on expanding its presence within the larger Medicare market, which represents a significant opportunity for revenue growth, is expected to enhance overall financial performance. The recent favorable ruling from CMS that includes the MyoPro under Medicare Part B benefits further broadens the market potential for Myomo, positioning the company advantageously within the healthcare landscape.
Bears say
Myomo Inc. has lowered its 2025 revenue guidance significantly from a range of $50-53 million to $40-42 million, indicating a potentially troubling outlook for future earnings. Additionally, the quality of recent marketing efforts and pipeline conditions has not met expectations, resulting in decreased lead quality and poor pipeline conversions. Furthermore, the company's authorized insurance backlog has decreased from 272 in the previous quarter to 230, reflecting diminishing demand and a concerning trend in operational performance.
This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.
Myomo (MYO) Analyst Forecast & Price Prediction
Start investing in Myomo (MYO)
Order type
Buy in
Order amount
Est. shares
0 shares